Core Scientific EBIT

The latest EBIT for CORZ is $-1.1B as of June 2026. That compares with $-420M in the prior-year period — down 153.5% year over year. That is below the Technology sector average of $80T. Investors often review this figure alongside Core Scientific's historical trend and sector peers before judging valuation or financial health.

Over the past year, CORZ's EBIT moved from $-420M to $-1.1B — a 153.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Core Scientific's operating scale or balance-sheet position.

Against Technology companies, CORZ currently prints $-1.1B for EBIT, while the sector average sits near $80T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Core Scientific's growth, margins, and balance sheet.

A EBIT figure of $-1.1B for CORZ is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Technology average is about $80T. Explore the charts below for those layers of context.

After noting CORZ's EBIT ($-1.1B), review year-over-year change from $-420M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.